Summary
All provided claims concern pricing, insurance copays/coinsurance, formulary tiers, pharmacy cash prices, and discount programs, but no FDA prescribing information label text/sections were provided to verify any of these statements. Therefore, every evaluated claim is unsupported/absent from the provided label material.
Category Scores
Accurate Statements
Unsupported Statements
Cardura (doxazosin) pricing is not fixed because it depends on factors like dose strength, tablet quantity, whether you use a brand or generic, your pharmacy, and whether you have insurance or a discount card.
No pricing, pharmacy cost, insurance cost-sharing, or discount-card/list-price information was found in the provided label sections (absent from the label).
Generic doxazosin is often less expensive than the brand-name Cardura, especially for common tablet strengths.
No comparative brand-versus-generic pricing information is present in the provided label sections (absent from the label).
With insurance, a Cardura copay may be a fixed copay or a percentage coinsurance.
No insurance copay/coinsurance structure is stated in the provided label sections (absent from the label).
The insurance copay for Cardura can differ based on the plan’s formulary tier (preferred generic vs brand, and preferred vs non-preferred).
No formulary-tier or plan-based cost-sharing/cost differences are described in the provided label sections (absent from the label).
Many pharmacies offer in-store cash prices.
No statements regarding pharmacy cash prices are included in the provided label sections (absent from the label).
Discount programs can sometimes lower the cost versus the standard list price.
No discount-program or list-price comparison content is found in the provided label sections (absent from the label).
Contradictions
Important Omissions
FDA prescribing information content used for compliance checking (label sections/text) was not provided.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The statements are non-clinical (pricing/insurance/payment logistics). While they are unsupported by the provided prescribing information material, they do not directly assert dosing or safety-critical clinical actions based on the supplied claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple unsupported non-label claims about pricing, insurance copays/coinsurance, formulary tiers, cash prices, and discount programs; no FDA label text was provided for verification.
Suggested Improvement
Restrict statements to FDA label-supported sections (e.g., boxed warnings, contraindications, warnings/precautions, dosing/administration) and provide the exact FDA prescribing information text/section excerpts used for the audit.